Novartis India Balance Sheet Health
Financial Health criteria checks 6/6
Novartis India has a total shareholder equity of ₹7.0B and total debt of ₹0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are ₹8.7B and ₹1.7B respectively. Novartis India's EBIT is ₹467.1M making its interest coverage ratio -1.3. It has cash and short-term investments of ₹4.9B.
Key information
0%
Debt to equity ratio
₹0
Debt
| Interest coverage ratio | -1.3x |
| Cash | ₹4.90b |
| Equity | ₹7.02b |
| Total liabilities | ₹1.68b |
| Total assets | ₹8.71b |
Recent financial health updates
No updates
Recent updates
Factors Income Investors Should Consider Before Adding Novartis India Limited (NSE:NOVARTIND) To Their Portfolio
Apr 04
Weak Financial Prospects Seem To Be Dragging Down Novartis India Limited (NSE:NOVARTIND) Stock
Jan 29Are Dividend Investors Getting More Than They Bargained For With Novartis India Limited's (NSE:NOVARTIND) Dividend?
Jan 02
Novartis India Limited's (NSE:NOVARTIND) Popularity With Investors Is Under Threat From Overpricing
Dec 07We're Not Counting On Novartis India (NSE:NOVARTIND) To Sustain Its Statutory Profitability
Nov 08Is Novartis India Limited's (NSE:NOVARTIND) Recent Performance Market's Way Of Responding to Its Mixed Financials?
Oct 11Financial Position Analysis
Short Term Liabilities: NOVARTIND's short term assets (₹6.0B) exceed its short term liabilities (₹1.4B).
Long Term Liabilities: NOVARTIND's short term assets (₹6.0B) exceed its long term liabilities (₹291.6M).
Debt to Equity History and Analysis
Debt Level: NOVARTIND is debt free.
Reducing Debt: NOVARTIND had no debt 5 years ago.
Debt Coverage: NOVARTIND has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: NOVARTIND has no debt, therefore coverage of interest payments is not a concern.
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/01/22 13:50 |
| End of Day Share Price | 2023/10/25 00:00 |
| Earnings | 2023/09/30 |
| Annual Earnings | 2023/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Novartis India Limited is covered by 4 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Amit Gupta | Batlivala & Karani Securities India Pvt. Ltd. |
| Anil Burra | FirstCall Research |
| Suhani Adilabadkar | FirstCall Research |